IL-7 armed binary CAR T cell strategy to augment potency against solid tumors.

Area of Science:

• Immunology
• Oncology
• Biotechnology

Background:

• Chimeric antigen receptor (CAR) T cell therapy shows promise for B-cell malignancies but faces challenges in solid tumors, including antigen loss, heterogeneity, and poor T cell persistence.
• Current strategies often struggle to simultaneously address antigen diversity and T cell longevity within the tumor microenvironment.

Purpose of the Study:

• To develop and evaluate a novel CAR T cell strategy for solid tumors that overcomes antigen heterogeneity and enhances T cell persistence.
• To investigate the efficacy of a dual-targeting CAR T cell system engineered with transgenic IL-7 cytokine support.

Main Methods:

• Engineered T cells to express independent CARs targeting two distinct solid tumor antigens: PSCA and MUC1.
• Incorporated transgenic Interleukin-7 (IL-7) cytokine and receptor (IL-7Rα) expression within the CAR T cells to promote localized persistence and function.

Main Results:

• The dual-targeting CAR T cell strategy with IL-7 support demonstrated superior anti-tumor potency and durable effects in a pancreatic tumor model.
• Compared to single-target CARs or dual-target CARs without IL-7, this enhanced binary approach led to significant T cell expansion and sustained anti-tumor activity.
• The combination of dual antigen recognition and cytokine support effectively addressed tumor heterogeneity and improved T cell longevity.

Conclusions:

• Transgenic IL-7 armed binary CAR T cells represent a potent therapeutic strategy for solid tumors.
• This approach holds potential for improving the efficacy of CAR T cell therapies in challenging solid tumor indications.